2B70:XETRA:XETRA-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 6.029

Change

-0.02 (-0.36)%

Market Cap

USD 0.52B

Volume

0.13M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.34 (-0.66%)

USD 446.30B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.11 (-0.66%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.24 (-0.88%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.27 (-0.95%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.09 (-0.36%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

-1.08 (-0.76%)

USD 102.09B
JARI:XETRA Amundi Index Solutions - Amund..

-0.66 (-1.44%)

USD 101.20B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.33 (-0.65%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.24 (-0.23%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-1.62 (-0.27%)

USD 80.38B

ETFs Containing 2B70:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.63% 37% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.63% 35% F 40% F
Trailing 12 Months  
Capital Gain 6.82% 43% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.82% 41% F 46% F
Trailing 5 Years  
Capital Gain 21.72% 52% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.72% 46% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 5.35% 47% F 48% F
Dividend Return 5.35% 46% F 46% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.45% 46% F 56% F
Risk Adjusted Return 39.75% 39% F 44% F
Market Capitalization 0.52B 66% D+ 58% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.